EE42 Economic Evaluation of Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in Japan
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.348
https://www.valueinhealthjournal.com/article/S1098-3015(23)00448-5/fulltext
Title :
EE42 Economic Evaluation of Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in Japan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00448-5&doi=10.1016/j.jval.2023.03.348
First page :
Section Title :
Open access? :
No
Section Order :
11734